Cargando…
Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study
BACKGROUND: Myasthenia gravis (MG) is an autoimmune neuromuscular disease, with gut microbiota considered to be a pathogenetic factor. Previous pilot studies have found differences in the gut microbiota of patients with MG and healthy individuals. To determine whether gut microbiota has a pathogenet...
Autores principales: | Totzeck, Andreas, Ramakrishnan, Elakiya, Schlag, Melina, Stolte, Benjamin, Kizina, Kathrin, Bolz, Saskia, Thimm, Andreas, Stettner, Mark, Marchesi, Julian R., Buer, Jan, Kleinschnitz, Christoph, Verhasselt, Hedda Luise, Hagenacker, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361534/ https://www.ncbi.nlm.nih.gov/pubmed/34394728 http://dx.doi.org/10.1177/17562864211035657 |
Ejemplares similares
-
Fungal Gut Microbiome in Myasthenia Gravis: A Sub-Analysis of the MYBIOM Study
por: Verhasselt, Hedda Luise, et al.
Publicado: (2023) -
Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
por: Totzeck, Andreas, et al.
Publicado: (2019) -
CIDP, myasthenia gravis, and membranous glomerulonephritis – three autoimmune disorders in one patient: a case report
por: Bolz, Saskia, et al.
Publicado: (2018) -
Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters
por: Stolte, Benjamin, et al.
Publicado: (2021) -
Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen
por: Brakemeier, Svenja, et al.
Publicado: (2021)